[Classification of hepatitis C virus into two major groups in serologic activity: correlation with response to interferon].
Genotypes of HCV have been reported to be one of the predictors of response to IFN therapy in patients with chronic hepatitis C. HCV genotypes were determined enzyme-linked immunoblot assay based on group I and II specific recombinant peptides of the NS-4 region (amino acid No. 1676-1670). We examined the correlation between HCV groups and response to IFN in patients with chronic hepatitis C. Among the 84 patients with chronic hepatitis C who underwent IFN treatment, 16 of 51 (31.4%) patients with group I and 12 of 23 (52.2%) patients with group II showed complete sustained response. These results suggest that HCV group assay may improve the ability to predict IFN treatment outcomes.
Matsushima
T
T
Third Department of Internal Medicine, Hokkaido University Medical School.
Karino
Y
Y
Hige
S
S
Toyota
J
J
D002908:Chronic Disease; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics; D006526:Hepatitis C / Q000628:therapy; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D007372:Interferons / Q000627:therapeutic use*; D016896:Treatment Outcome
D007372:Interferons